IndraLab

Statements


Histone deacetylase inhibitors decreases the amount of USP17L2. 1 / 1
| 1

reach
"Most interestingly, we found that histone deacetylase inhibitors (HDACis) could significantly activate MGMT and DUB3 expression; the combined administration of HDACis and PaTrin-2 led to the ideal therapeutic effect."